On Thursday, TECO Energy, Inc. (NYSE:TE)’s shares inclined 0.07% to $26.72.
For the third successive year, the residential customers of TECO Peoples Gas have ranked the utility highest in customer satisfaction among midsized natural gas companies in the south region in the J.D. Power annual study.
TECO Peoples Gas ranked highest in customer satisfaction in residential natural gas service among midsized gas utilities in the south region, which comprises eight states. The company ranked the highest in price, communications and customer service among its peers in the region segment.
J.D. Power’s 2015 Gas Utility Residential Customer Satisfaction Study is based on more than 66,000 responses from residential customers of the 83 largest gas utilities across the continental United States. The study was conducted between September 2014 and July 2015. It analyzed satisfaction in six categories: billing and payment, price, corporate citizenship, communications, customer service and field service.
TECO Energy, Inc., an electric and gas utility holding company, engages in the regulated electric and gas utility operations. It generates, purchases, transmits, distributes, and sells electric energy to retail customers, in addition to utilities and other resellers of electricity in West Central Florida; and has electric generating plants with a winter peak generating capacity of 4,668 megawatts.
Amgen, Inc. (NASDAQ:AMGN)’s shares gained 1.81% to $153.91.
Amgen (AMGN) and Dezima Pharma B.V. (Dezima) declared that the companies have reached a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. Dezima shareholders have approved the agreement.
Dezima’s lead molecule is TA-8995, an oral, once-daily cholesteryl ester transfer protein (CETP) inhibitor. In a Phase 2b clinical trial for dyslipidemia, TA-8995 reduced low-density lipoprotein cholesterol (LDL-C) by 45 to 48 percent contrast to baseline. LDL-C reduction was compriseent when TA-8995 was administered as monotherapy or in combination with statins. The most common adverse events were nasopharyngitis and headache.
Under the terms of the agreement, Amgen will pay $300 million in cash at closing and up to $1.25 billion in additional payments if certain development and sales milestones are achieved. Low single-digit royalties will be paid on net product sales above a certain threshold. The agreement is subject to customary closing conditions, counting regulatory approvals, and is predictable to close in the fourth quarter of this year. Following the completion of the transaction, Dezima Pharma, which originally licensed rights to TA-8995 from Mitsubishi Tanabe Pharma Corporation (MTPC), will become a wholly owned partner of Amgen. MTPC will receive from Dezima a portion of the upfront payment, future development and sales milestone payments, and royalties on net product sales if a certain threshold is reached. MTPC will also retain development and commercialization rights to TA-8995 in certain territories in Asia, counting Japan.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
At the end of Thursday’s trade, AstraZeneca plc (ADR) (NYSE:AZN)‘s shares surged 0.57% to $33.81.
llergan plc (AGN) declared that its infectious disease portfolio will be featured in 24 abstracts highlighting new data at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2015, which takes place from September 17-21, 2015 in San Diego.
Allergan will present data from studies further evaluating: the antimicrobial activity against certain gram negative isolates and pharmacokinetics of AVYCAZ™ (ceftazidime-avibactam); in-vitro activity and susceptibility testing methodologies for DALVANCE® (dalbavancin) (ABSSSI); and the microbiologic activity, pharmacodynamics and efficacy of TEFLARO® (ceftaroline fosamil) for the treatment of acute skin and skin structure infections (ABSSSI).
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide.
EXCO Resources Inc (NYSE:XCO), ended its Thursday’s trading session with -2.83% loss, and closed at $0.923.
EXCO Resources, Inc. (XCO) declares the closing under the Services and Investment Agreement with Energy Planned Advisory Services LLC (“ESAS”), a wholly owned partner of Bluescape Resources Company LLC (“Bluescape”). Highlights comprise:
- John Wilder, Executive Chairman of Bluescape Resources Company LLC, has joined EXCO’s Board of Directors and been designated EXCO’s Executive Chairman.
- John Wilder and ESAS will continue to lead EXCO’s transformational strategy that focuses on six core areas: 1) liability administration, 2) operational performance, 3) capital deployment, 4) risk administration, 5) portfolio repositioning, and 6) performance administration.
- ESAS has purchased from EXCO 5,882,353 shares of EXCO’s common stock for a purchase price of $10 million at $1.70 per share (the ten day volume weighted average price of EXCO’s common stock as of March 30, 2015).
EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
